Case Studies
AHA to HRSA: Implement 340B Drug Ceiling Price Rule Without Further Delay
AHA comments to HRSA regarding proposed rule that would further delay the effective date for implementing final regulations regarding the 340B Drug Pricing Program ceiling price and drug manufacturers’ civil monetary penalties (CMPs) for violations of the ceiling price.
Key Resources
Related Resources
Letter/Comment
Letter/Comment
Case Studies